Liv Hospital Ankara | Pulmonology Department

Research site

(Unclaimed)

Location

Bestekar Street, 8 Çankaya, ANKARA, Ankara, Turkey

Site insights

Top conditions

Top treatments

Pembrolizumab

Dexamethasone

Pomalidomide

Bortezomib

BNT327

Cyclophosphamide

Fianlimab

Cemiplimab

Daratumumab

Atezolizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

21 of 24 total trials

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (IMforte)

Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab...

Active, not recruiting

Small-Cell Lung Cancer

Drug: Atezolizumab

Drug: Lurbinectedin

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment (MonumenTAL-3)

The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP)...

Active, not recruiting

Relapsed or Refractory Multiple Myeloma

Drug: Talquetamab

Drug: Dexamethasone

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (MonumenTAL-6)

The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) w...

Enrolling

Multiple Myeloma

Drug: Elotuzumab

Drug: Bortezomib

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9)

The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alter...

Active, not recruiting

Relapsed or Refractory Multiple Myeloma

Drug: Dexamethasone

Drug: Pomalidomide

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)

The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in comb...

Enrolling

Multiple Myeloma

Drug: Lenalidomide

Drug: Talquetamab

A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection (REZILIENT4)

The purpose of this study is to compare the efficacy of zipalertinib combined with adjuvant chemotherapy versus placebo combined with adjuvant chemot...

Enrolling

NSCLC, Stage IB-IIIA

Exon 20

Drug: Cisplatin

Drug: Pemetrexed

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product (Keytruda®).

Active, not recruiting

Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Drug: ABP 234

Drug: Pembrolizumab (EU)

A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

The study will compare the efficacy and safety of entrectinib with crizotinib in participants with advanced or metastatic ROS1 non-small cell lung ca...

Active, not recruiting

Carcinoma, Non-Small-Cell Lung

Drug: Entrectinib

Drug: Crizotinib

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide,...

Enrolling

Relapsed or Refractory Multiple Myeloma

Drug: Pomalidomide

Drug: mezigdomide

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab (also called REG...

Active, not recruiting

Advanced Non-Small Cell Lung Cancer

Drug: cemiplimab

Drug: Placebo

A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma (OLYMPIA-2)

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously u...

Active, not recruiting

Follicular Lymphoma (FL)

Drug: Odronextamab

Drug: Vincristine

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma (OLYMPIA-1)

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously u...

Enrolling

Follicular Lymphoma (FL)

Drug: Cyclophosphamide

Drug: Rituximab

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

This study is researching an experimental drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and platinum-doub...

Active, not recruiting

Resectable Non-small Cell Lung Cancer

Drug: Cisplatin

Drug: Cemiplimab

Locations recently updated

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizum...

Enrolling

Solid Tumors

Hematologic Malignancies

Drug: Pembrolizumab

Biological: MK-4280A

Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) (Eucalyptus)

The primary objective of this study is to demonstrate pharmacokinetic (PK) similarity ABP 234 with pembrolizumab.

Enrolling

Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)

Drug: ABP 234

Drug: Pembrolizumab

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patien...

Enrolling

Metastatic Non-Small Cell Lung Cancer

Advanced Non-Small Cell Lung Cancer

Drug: Pembrolizumab

Drug: Adagrasib

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin)...

Enrolling

Extensive-stage Small-cell Lung Cancer

Drug: Pumitamig

Drug: Etoposide

Locations recently updated

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC).This study includes t...

Enrolling

Non-small Cell Lung Cancer

Drug: Pumitamig

Drug: Pembrolizumab

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

This is a global, multicenter, randomized, open-label study, with an adaptive design. The main objective of the study is to measure the efficacy and...

Enrolling

Metastatic Urothelial Cancer

Drug: Pembrolizumab

Drug: BT8009

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. (Be6A Lung-02)

The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alon...

Enrolling

Carcinoma, Non-Small-Cell Lung (NSCLC)

Carcinoma, Non-Small-Cell Lung

Drug: Pembrolizumab

Drug: Sigvotatug Vedotin